BIIB vs CRVO: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

BIIB is the larger of the two ($37.11B market cap): the incumbent the market prices for continued execution (15.44x forward earnings, beta 0.09). CRVO is the smaller challenger ($21.03M), priced similarly on forward earnings (-1.06x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

BIIB vs CRVO: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricBIIBCRVOWhat it tells you
Market cap$37.11B$21.03MSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E15.44-1.06Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.09-3.99Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range91% of range1% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.961.21How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how BIIB and CRVO affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BIIB and CRVO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BIIB and CRVO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Biogen (BIIB) do?

Biogen is a Cambridge, Massachusetts biotechnology company built on neuroscience. Its historic core is multiple sclerosis (Tysabri, Tecfidera, Vumerity), and it co-developed the spinal muscular atrophy drug Spinraza with Ionis. Its growth story now centers on Leqembi, the Alzheimer's antibody it markets with partner Eisai, alongside newer rare-disease products Skyclarys (Friedreich's ataxia) and Qalsody (ALS). In 2026 it closed the roughly $5.6 billion acquisition of Apellis Pharmaceuticals, adding the retinal drug Syfovre for geographic atrophy and Empaveli for rare blood and kidney diseases. Beyond neuroscience it is pushing into immunology, where litifilimab (which holds FDA Breakthrough Therapy Designation in cutaneous lupus) reported sustained 52-week skin improvement in the AMETHYST study in late September 2026.

Full BIIB guide

What does CervoMed (CRVO) do?

CervoMed is a clinical-stage biopharmaceutical company developing neflamapimod, an oral small-molecule inhibitor of p38 MAP kinase alpha, which the company says targets the neuroinflammation and synaptic dysfunction that drive neurodegenerative disease. Its lead program is in dementia with Lewy bodies (DLB), a common and serious form of dementia with few approved treatments. CervoMed is also exploring neflamapimod in additional indications such as frontotemporal disorders, nonfluent variant primary progressive aphasia, and recovery-related neurology programs, but DLB is the central driver of the story.

Full CRVO guide

BIIB vs CRVO: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • BIIB drivers: Leqembi Alzheimer's ramp; Rare-disease and new-product portfolio.
  • CRVO drivers: Differentiated mechanism in a high-unmet-need disease; Supportive secondary and biomarker data.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The legacy MS business (Tecfidera, Tysabri) continues to decline against generics and biosimilars. For CRVO, cervoMed is an extremely speculative micro-cap with no approved products and no product revenue, so its fate hinges on a single asset, neflamapimod, in a disease where its key Phase 2b already missed its primary endpoint.

BIIB or CRVO: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BIIB if you believe its drivers more; CRVO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BIIB and CRVO guides.

BIIB vs CRVO: the full fundamentals

BIIB. Biogen trades at about 14 times forward earnings, still below many large-cap drugmakers, while the trailing P/E near 42 reflects GAAP charges tied to the Apellis deal rather than the underlying run rate. Analysts expect 2026 EPS of about $12.53 and a rebound to about $16.52 in 2027, and the average price target of about $244 sits only slightly above the current price after the rally. The October 28 report (consensus EPS about $2.00) is the next check on whether the beats continue.

CRVO. A single-asset clinical biotech like CervoMed cannot be valued on earnings, revenue, or P/E because it has none; its market value reflects a probability-weighted guess at neflamapimod's commercial potential, discounted heavily for trial and financing risk. At about $34 million the market cap is only modestly above the roughly $25 million of cash, so investors are assigning little value to the drug itself, even as five covering analysts carry a mean target near $15. Partnering news, the November 2026 CTAD data, and financing terms are the variables that can swing the implied value most.

Headline figures (approximate, October 2026): BIIB shows revenue (ttm) ~$10.0B, q2 2026 revenue growth ~3% YoY, q2 2026 non-gaap eps ~$3.60 (vs ~$2.03 est.), net income (ttm) ~$835M (~8% margin); CRVO shows product revenue None (clinical-stage; grant revenue lapsed to $0 in 2026), net loss (q2 2026 / ttm) ~$6.6 million / ~$30.4 million, eps (q2 2026, actual vs estimate) -$0.64 vs -$0.86, cash & equivalents (jun 30, 2026) ~$24.9 million, no debt.

The bottom line: BIIB vs CRVO

BIIB and CRVO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BIIB and CRVO exposure against your real portfolio. It is not an investment adviser.

Wondering how BIIB or CRVO fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Biogen

Ask Walnut's AI anything about BIIB and see how it fits what you own.

FAQ

What is the difference between BIIB and CRVO?

+

Biogen is a Cambridge, Massachusetts biotechnology company built on neuroscience. CervoMed is a clinical-stage biopharmaceutical company developing neflamapimod, an oral small-molecule inhibitor of p38 MAP kinase alpha, which the company says targets the neuroinflammation and synaptic dysfunction that drive neurodegenerative disease. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is BIIB or CRVO the better stock?

+

Neither is universally better. BIIB is the larger incumbent; CRVO is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, BIIB or CRVO?

+

On forward P/E (as of November 2026), BIIB trades at 15.44x and CRVO at -1.06x, so CRVO is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both BIIB and CRVO?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of BIIB vs CRVO?

+

BIIB: The legacy MS business (Tecfidera, Tysabri) continues to decline against generics and biosimilars. Leqembi faces direct competition from Eli Lilly's Kisunla and lingering questions about diagnostic access, infusion logistics, and payer coverage, so its ramp could disappoint. Large acquisitions like Apellis add integration and execution risk, raised debt to about $8.4 billion, and carry contingent value payments tied to Syfovre sales that create uncertain future costs; GAAP net income over the last twelve months was only about $835 million, which is why the trailing P/E sits near 42. Biotech pipelines carry binary clinical and regulatory outcomes, and the upcoming lupus readouts are exactly that kind of event. After a 66% one-year rally to near the 52-week high, the share price leaves less room for disappointment than the old discount did, and consensus still expects 2026 EPS of about $12.53, down about 18% from 2025. CRVO: CervoMed is an extremely speculative micro-cap with no approved products and no product revenue, so its fate hinges on a single asset, neflamapimod, in a disease where its key Phase 2b already missed its primary endpoint. Outcomes are binary: a failed or delayed Phase 3, a regulatory setback, or an inability to secure a partner could sharply reduce or wipe out the value, and the Phase 3 start now depends explicitly on finding that partner. Management has flagged substantial doubt about the company's ability to continue as a going concern, and with about $24.9 million of cash at June 30, 2026 against a trailing net loss of about $30 million, further capital raises are likely and could heavily dilute existing shareholders; the share count has already risen to roughly 15 million. The nfvPPA data so far is open-label biomarker data without a control group. Single-asset concentration, ongoing losses, and reliance on external financing make the stock high-risk and capable of total loss, as its roughly 71% decline in 2026 shows.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BIIB or CRVO; figures are approximate and dated (as of November 2026). Verify current data before investing.